Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

For example, in diffuse large B-cell lymphoma, which is one of the most frequent hematological neoplasia, CSF1R is identifying tumor-associated macrophages (TAMs) that are one of the most important ...